A Comparison of Safety and Treatment in Subjects With Osteoarthritis Taking Low Dose Aspirin

This study has been completed.
Information provided by:
ClinicalTrials.gov Identifier:
First received: September 12, 2005
Last updated: July 20, 2010
Last verified: July 2010
The purpose of this study is to compare the gastroduodenal ulceration rate, gastrointestinal complication rate and non-steroidal anti-inflammatory drug-associated dyspepsia between lansoprazole, naproxen and celecoxib, taken once daily (QD) or twice daily (BID), in participants with osteoarthritis taking low dose aspirin.

Condition Intervention Phase
Peptic Ulcer
Drug: Lansoprazole and naproxen and aspirin
Drug: Celecoxib and aspirin
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Phase 3 Study to Compare the Efficacy and Safety of Lansoprazole 30 mg QD and Naproxen 500 mg BID Versus Celecoxib 200 mg QD in Risk Reduction of Non Steroidal Anti-Inflammatory-Associated Ulcers in Osteoarthritis Subjects Taking Low Dose Aspirin

Resource links provided by NLM:

Further study details as provided by Takeda:

Primary Outcome Measures:
  • Gastroduodenal ulcers at final visit [ Time Frame: Week 12 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Proportion of subjects with GI complications (GI bleeding, perforation and gastric outlet obstruction) [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
  • Severity of each dyspepsia symptom (abdominal pain, nausea, vomiting, heartburn, fullness, and belching) and combined dyspepsia scores. [ Time Frame: Weeks 4,8, and 12 ] [ Designated as safety issue: No ]
  • Proportion of subjects with dyspepsia at weeks 4, 8, and 12 that did not have dyspepsia at baseline. [ Time Frame: Weeks 4,8, and 12 ] [ Designated as safety issue: No ]
  • Proportion of subjects without dyspepsia at weeks 4, 8, and 12 who had dyspepsia at baseline. [ Time Frame: Weeks 4, 8, and 12 ] [ Designated as safety issue: No ]
  • Scores of each SODA scale (pain intensity, non-pain symptoms, and satisfaction) for subjects with dyspepsia. [ Time Frame: Weeks 4, 8, and 12 ] [ Designated as safety issue: No ]
  • The change from baseline SODA scale for subjects with dyspepsia at baseline. [ Time Frame: Weeks 4, 8, and 12 ] [ Designated as safety issue: No ]

Enrollment: 1045
Study Start Date: July 2003
Study Completion Date: July 2004
Primary Completion Date: July 2004 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Lansoprazole 30 mg QD + Naproxen 500 mg BID
(and added aspirin)
Drug: Lansoprazole and naproxen and aspirin
Lansoprazole 30 mg, capsules, orally once daily; Naproxen 500 mg, capsules, orally, twice daily; and aspirin 81 mg or 325 mg, tablets, orally, once daily for up to 12 weeks.
Active Comparator: Celecoxib 200 mg QD
(and added aspirin)
Drug: Celecoxib and aspirin
Celecoxib 200 mg, capsules, orally once daily and aspirin 81 mg or 325 mg, tablets, orally, once daily for up to 12 weeks.

Detailed Description:
This study was designed to compare the effectiveness of reducing the incidence of gastroduodenal ulcers between lansoprazole 30mg QD + naproxen 500mg BID vs celecoxib 200mg QD in subjects with osteoarthritis taking low dose aspirin. Approximately 100 sites across the U.S. will enroll subjects with normal endoscopic findings and negative H.pylori. The duration of the study will be a maximum of 14 weeks including a screening period of up to 2 weeks and a 12 week treatment period. Gelusil will be provided for dyspepsia symptom rescue.

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Must require the chronic use of a non-steroidal anti-inflammatory drug for the treatment of osteoarthritis.
  • Must be taking daily aspirin for cardiovascular prophylaxis.
  • Clinical Laboratory values within normal limits for this population

Exclusion Criteria:

  • History of gastric, duodenal or esophageal surgery except simple oversew of an ulcer.
  • Evidence of uncontrolled, clinically significant disease.
  • History of cancer within the past 5 years.
  • Presence of gastroduodenal ulcers, esophageal ulcer or >= 10 gastroduodenal erosions during the screening endoscopy. Known history of gastroduodenal ulcer or bleeding within the past year. Esophageal stricture requiring dilatation.
  • Presence of Barrett's esophagus with dysplastic changes.
  • Systemic disease affecting the esophagus or a history of caustic or physiochemical trauma or irradiation to the esophagus.
  • Sero-tests positive for H. pylori.
  • Evidence of Zollinger-Ellison syndrome, esophageal varices, cholecystitis, or pancreaticobiliary tract disease.
  • Requires treatment with an excluded medication such as proton pump inhibitors, histamine H2 receptor antagonists, antacids, corticosteroids, lithium, fluconazole, misoprostol, probenecid, methotrexate, anticoagulants, St. John's wart, dong quai, feverfew, garlic, ginger, horse chestnut, red clover or white willow supplements or bisphosphonates.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00175032

Sponsors and Collaborators
Study Director: Medical Director Takeda
  More Information

Additional Information:
Responsible Party: Sr. VP Clinical Sciences, Takeda Global Research & Development Center, Inc.
ClinicalTrials.gov Identifier: NCT00175032     History of Changes
Other Study ID Numbers: LAN-0003-0041  U1111-1114-2275 
Study First Received: September 12, 2005
Last Updated: July 20, 2010
Health Authority: United States: Food and Drug Administration

Keywords provided by Takeda:
Low dose aspirin
Peptic Ulcer
gastric ulcer
duodenal ulcer

Additional relevant MeSH terms:
Peptic Ulcer
Digestive System Diseases
Duodenal Diseases
Gastrointestinal Diseases
Intestinal Diseases
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Stomach Diseases
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Anti-Ulcer Agents
Antirheumatic Agents
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Fibrin Modulating Agents
Fibrinolytic Agents
Gastrointestinal Agents
Gout Suppressants

ClinicalTrials.gov processed this record on May 23, 2016